Mounjaro NHS Criteria: What You Need to Know Before Applying

NICE approved tirzepatide (Mounjaro) for NHS use in December 2024 under guidance TA1026, but access is being rolled out in phases — not everyone who qualifies for the medicine qualifies for NHS funding yet.
Right now, NHS funding requires a BMI of 40 or above plus four or more qualifying conditions from a specific list of five; a second cohort (BMI 35–39.9) became eligible from 23 June 2026.
For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, BMI thresholds are set 2.5 kg/m² lower throughout all phases.
Meeting the criteria does not guarantee access, NHS patients must also take part in a supported diet and activity programme, and waiting lists at specialist services vary considerably by area.

The NHS criteria for Mounjaro are stricter than most people expect. Under NICE guidance (TA1026), adults must have a BMI of 40 or above alongside at least four qualifying weight-related conditions to access tirzepatide through the NHS right now. A common belief is that any GP can simply prescribe Mounjaro if your BMI is high enough — that is not how it works. These are prescription-only medicines, and suitability is assessed by a prescriber who weighs up your full health picture, not just a single number.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The phased rollout explained, and what to do if you don't qualify yet

The biggest myth: a high BMI alone gets you Mounjaro on the NHS

Many people arrive at their GP assuming that a BMI over 40 is the key that opens the door to tirzepatide on the NHS. It is not, at least not on its own. NICE's recommendation (TA1026, published December 2024 and updated September 2025) sets out phased eligibility thresholds, and the current phase requires both a BMI of 40 or above and four or more conditions from a fixed list of five: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. If you have three of those five, you don't qualify under the current cohort, even with a BMI of 45. That surprises a lot of people.

The five-condition requirement reflects the phased nature of the NHS rollout. NICE TA1026 and NHS England's commissioning guidance detail how eligibility broadens incrementally, allowing the health service to manage demand on specialist weight management services. You can read the full recommendation set on NICE's TA1026 guidance page.

One quick thing worth doing right now: pull up our summary of the NHS Mounjaro criteria for 2025 and count your qualifying conditions honestly before your GP appointment. It takes under a minute and means you walk in knowing where you stand rather than finding out mid-conversation.

How the NHS phased rollout actually works

The rollout is structured around cohorts that broaden over time. From June 2025, the first cohort opened: BMI 40 or above with four or more of the five qualifying conditions. A second cohort activated on 23 June 2026, covering adults with a BMI between 35 and 39.9 alongside four or more conditions. A further phase, expected around March 2027, will extend to those with a BMI of 40 or above and three qualifying conditions.

From 1 April 2026, some GP practices have been able to prescribe tirzepatide directly under the updated GP contract (QOF 2026/27). Participation is optional for practices, so whether your surgery offers this depends entirely on where you are. NHS England's detailed information on weight management injections outlines what wraparound care patients must access alongside the medicine. Every NHS patient receiving tirzepatide must engage with a supported diet and activity programme, the medicine does not come as a standalone prescription.

If you want a closer look at how criteria have shifted since the original NICE recommendation, our page on how the NHS Mounjaro criteria changed in 2026 traces the timeline in detail.

What happens when you don't meet the NHS criteria right now

Not meeting the current NHS thresholds is genuinely frustrating, particularly for people who have struggled with their weight for years and can see tirzepatide's trial results, an average body-weight reduction of around 20–21% at the highest dose over 72 weeks, as reported in SURMOUNT-1 in the New England Journal of Medicine. The clinical case for treatment doesn't disappear just because a cohort threshold hasn't opened yet.

A private prescription through a GPhC-registered online pharmacy is the legal alternative. The licensed eligibility for private prescribing is broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be assessed. Tirzepatide is still a prescription-only medicine on the private route, you cannot simply buy Mounjaro over the counter, and any seller offering it without a prescription is acting outside the law.

For context on what private treatment involves and costs, our overview of Mounjaro weight loss NHS criteria and the Mounjaro treatment page explain both routes side by side. You can also read more about how to access Mounjaro online through a regulated UK pharmacy. The private route has no waiting list, but clinical assessment by a prescriber is still required before any treatment is dispensed.

Private assessment through a registered UK pharmacy

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. If treatment is clinically suitable and your order is placed before midday, your prescription is dispatched the same day and arrives free by DPD the following working day, in plain unbranded packaging.

You can verify our pharmacy on the GPhC register at any point, our premises registration number is 9012878, searchable directly on the GPhC pharmacy register. That's a useful check to run on any online pharmacy before you hand over personal health information.

Weight is a health condition shaped by biology. If the NHS door is not open to you yet, there is a clinically rigorous private route available. Our prescribers can assess whether Mounjaro is appropriate for your situation. Speak to our prescribers through a free consultation to find out where you stand.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions